Varian and the Cincinnati Children's/UC Health Proton Therapy Center Complete Enrollment of FAST-01, First Human Clinical Trial of FLASH Therapy for Cancer

Trial, designed in collaboration with the FlashForward™Consortium, launched and treated first subject in November 2020

News provided by

Oct 25, 2021, 11:00 ET

PALO ALTO, Calif., and CINCINNATI, Oct. 25, 2021 /PRNewswire/ -- Varian, a Siemens Healthineers company, and the Cincinnati Children's/UC Health Proton Therapy Center today announced the completion of enrollment in FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases), the first human clinical trial of FLASH therapy.

The FAST-01 trial, which is evaluating clinical workflow feasibility of the FLASH therapy and treatment-related side effects, met its enrollment target of 10 participants with bone metastases in the extremities. The clinical trial, informed by years of preclinical work, was designed by experts at Varian and multiple centers in the FlashForward^TM Consortium, including Cincinnati's Children's/UC Health Proton Therapy Center and the New York Proton Center.

The FAST-01 trial is being led by John C. Breneman, M.D., principal investigator, and Medical Director of the Cincinnati Children's/UC Health Proton Therapy Center, UC Health radiation oncologist, and professor emeritus at the University of Cincinnati College of Medicine. "The completion of enrollment brings the clinical community one step closer to making an informed evaluation of FLASH therapy," said Dr. Breneman. "The team is looking forward to reviewing and sharing the findings, while also looking ahead toward the next clinical phase of research," he added.

The trial is supported by Emily Daugherty, M.D., assistant professor of radiation oncology at UC and a UC Health radiation oncologist, and Anthony Mascia, PhD, DABR, adjunct assistant professor of radiation oncology at UC and Director of Medical Physics at the Cincinnati Children's/UC Health Proton Therapy Center.

"Clinical trial investigators have worked diligently to complete enrollment of FAST-01 over the last year. Achieving this significant milestone is a vital step forward to demonstrating the feasibility of using FLASH therapy in a clinical setting and not just in a laboratory," said Agam Sharda, Vice President of Flash Solutions at Varian. "We are grateful to the trial subjects who, by virtue of their participation, have contributed to the advancement of FLASH technology, for the potential future benefit of others who may one day need to undergo treatment for cancer."

"Initial findings indicate that the Varian ProBeam^® system, modified to deliver FLASH therapy, is performing as planned during the study. To date, none of the trial participants have suffered any serious adverse events related to FLASH," said Ricky Sharma, M.D. Ph.D., Vice President of Clinical Affairs at Varian. "There is still much work and research to be done, and we are eager to explore all the clinical trial data."

About FLASH Therapy

FLASH therapy, an experimental treatment modality delivering radiation therapy at ultra-high dose rates in typically less than one second, may be over 100 times faster compared to conventional radiation therapy. The concept of ultra-high dose rate radiation delivery has been studied for many years. Dedicated research and development by the team at Varian and the clinical collaborators in the FlashForward Consortium has led towards the advancement of FLASH therapy to the clinical study stage. The FlashForward^™ Consortium, a 25-member group of institutions from around the world, includes over 150 experts in radiation oncology, translational sciences and medical physics. 

About Varian

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

About the Cincinnati Children's/UC Health Proton Therapy Center

The Cincinnati Children's/UC Health Proton Therapy Center, which opened in 2016, is one of only 35 in the United States. The Cincinnati center incorporates a $24 million, one-of-a-kind research facility, which includes a fully operational proton treatment room dedicated for just research along with integrated laboratories. The unique capabilities of the research center were instrumental in Cincinnati developing the world's first clinical trial of FLASH proton therapy. In addition, children and adults from around the world seek treatment for more than 30 types of cancer in two clinical therapy rooms at the center.

Press Contact
Lynne Tran
Corporate Communications
[email protected]

Investor Relations Contact
Siemens Healthineers Investor Relations

SOURCE Varian